AF9

5-[2,4-bis(azanyl)pyrimidin-5-yl]oxy-2-methoxy-4-propan-2-yl-benzenesulfonamide


Toggle HydrogenToggle Labels

Chemical Component Summary

Name5-[2,4-bis(azanyl)pyrimidin-5-yl]oxy-2-methoxy-4-propan-2-yl-benzenesulfonamide
SynonymsAF-219
Identifiers5-[2,4-bis(azanyl)pyrimidin-5-yl]oxy-2-methoxy-4-propan-2-yl-benzenesulfonamide
FormulaC14 H19 N5 O4 S
Molecular Weight353.397
TypeNON-POLYMER
Isomeric SMILESCC(C)c1cc(c(cc1Oc2cnc(nc2N)N)S(=O)(=O)N)OC
InChIInChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
InChIKeyHLWURFKMDLAKOD-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count43
Chiral Atom Count0
Bond Count44
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB15097 
NameGefapixant
Groups
  • approved
  • investigational
DescriptionIt has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks.[L48601] A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment or unexplained chronic cough (UCC) when no diagnosable cause for the cough can be determined.[L48596] Existing treatments for chronic cough have been associated with considerable side effects, in particular opioids such as [codeine] or [dextromethorphan].[L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough. It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.[L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]
Synonyms
  • Gefapixant citrate
  • Gefapixant
IndicationGefapixant is indicated in adult patients for the treatment of refractory or unexplained chronic cough.[L48591]
Categories
  • Amides
  • BCRP/ABCG2 Substrates
  • Benzene Derivatives
  • Cough and Cold Preparations
  • MATE 1 Substrates
ATC-Code
  • R05DB29
  • G01AE10
CAS number1015787-98-0

Drug Targets

NameTarget SequencePharmacological ActionActions
P2X purinoceptor 3MNCISDFFTYETTKSVVVKSWTIGIINRVVQLLIISYFVGWVFLHEKAYQ...unknownantagonist
P2X purinoceptor 2MAAAQPKYPAGATARRLARGCWSALWDYETPKVIVVRNRRLGVLYRAVQL...unknownantagonist
P-glycoprotein 1MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...unknownsubstrate
Multidrug and toxin extrusion protein 1MEAPEEPAPVRGGPEATLEVRGSRCLRLSAFREELRALLVLAGPAFLVQL...unknownsubstrate
Multidrug and toxin extrusion protein 2MDSLQDTVALDHGGCCPALSRLVPRGFGTEMWTLFALSGPLFLFQVLTFM...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL3716057
PubChem 24764487
ChEMBL CHEMBL3716057
CCDC/CSD EREMEV, EREMIZ